Associated Papers
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis.
Zhou M et al.
Journal of Lipid Research, 2019
Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
Gadaleta RM et al.
Scientific Reports, 2018
Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
Zhou M et al.
Hepatology (baltimore, Md.), 2016
A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J et al.
Science Translational Medicine, 2014
Select a paper to view details